Hims and Hers Health Inc vs Monster Beverage Corp — how do they compare? Hims and Hers Health Inc trades at $28.46 (market cap $6.55B), while Monster Beverage Corp trades at $43.56 (market cap $85.51B). The key difference: Monster Beverage Corp is far larger — about 13.1× Hims and Hers Health Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Monster Beverage Corp for 72 Days on average.
| HIMS | MNST | |
|---|---|---|
Market Cap | $6.55B | $85.51B |
Volume | 14,842,814 | 8,569,709 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $49.97 |
52-Week Low | $14.52 | $33.16 |
Typical Hold Time | 21 Days | 72 Days |
Enterprise Value | $7.25B | $83.81B |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.
The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS of $0.30 beat estimates, revenue grew to $8.29 billion in 2025, and net income margin stands at 23.08%. A 1:2 stock split is scheduled for August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, but technical indicators show selling pressure near current levels.
The outlook for MNST is mixed: robust earnings growth and zero long-term debt support upside, but high valuation ratios (P/E of 40.42) and bearish technicals pose near-term risks. International expansion, particularly a 35% sales surge overseas, offers growth potential, though regulatory challenges in markets like India and inflation pressures could hinder performance. The stock's rich pricing requires sustained execution to justify further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →